The NLRP3-specific inhibitor MCC950 and caspase-1 inhibitor Ac-YVAD significantly blocked the N-protein-induced NLRP3 inflammasome induction, suggesting the therapeutic potential of these inhibitors against COVID-19 [242]. Here, NLRP3 is linked to COVID-19.